New Zealand markets open in 3 hours 38 minutes

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
27.24+0.03 (+0.13%)
As of 02:21PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close27.20
Open27.17
Bid27.20 x 200
Ask27.24 x 100
Day's range26.95 - 27.34
52-week range25.92 - 32.36
Volume738,073
Avg. volume2,682,622
Market cap16.271B
Beta (5Y monthly)0.47
PE ratio (TTM)15.30
EPS (TTM)1.78
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yield0.84 (3.09%)
Ex-dividend date16 May 2024
1y target est44.33
  • GlobeNewswire

    Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buye

  • GlobeNewswire

    Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

    Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties exceeding $150 million annually Royalty Pharma to host investor call today,

  • GlobeNewswire

    Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

    Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to ca